

CITATION REPORT

List of articles citing

Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

DOI: 10.1016/j.jhep.2017.11.032

Journal of Hepatology, 2018, 68, 895-903.

Source: <https://exaly.com/paper-pdf/69672530/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
74	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1690-1698	6.1	19
73	HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. <i>Gastroenterology</i> , 2018 , 154, 2194-2208.e12	13.3	34
72	Viral resistance in HCV infection. <i>Current Opinion in Virology</i> , 2018 , 32, 115-127	7.5	8
71	Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study. <i>Virology Journal</i> , 2018 , 15, 150	6.1	14
70	Hepatitis C Guidance 2018 Update: AASLD-IDSAs Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1477-1492	11.6	344
69	HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. <i>Antiviral Research</i> , 2018 , 158, 178-184	10.8	13
68	Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , 2018 , 69, 603-607	13.4	44
67	Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. <i>Hepatology</i> , 2019 , 69, 513-523	11.2	57
66	Sofosbuvir susceptibility of genotype 1 to 6 HCV From DAA-naïve subjects. <i>Antiviral Research</i> , 2019 , 170, 104574	10.8	11
65	Management of HCV patients in cases of direct-acting antiviral failure. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 839-848	4.2	6
64	Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1276-1283	3.4	1
63	Optimizing the treatment strategy to achieve hepatitis C virus elimination in Mexico. <i>Revista De Gastroenterología De México (English Edition)</i> , 2019 , 84, 267-268	0.2	
62	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. <i>Journal of Infection</i> , 2019 , 79, 503-512	18.9	12
61	Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia. <i>Journal of Clinical Virology</i> , 2019 , 120, 84-87	14.5	5
60	Developments in the treatment of HCV genotype 3 infection. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 775-785	5.5	10
59	Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the Potency of Direct-Acting Antiviral Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	8
58	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019 , 71, 473-485	13.4	47

57	Pre-treatment antiviral resistance in Australians with chronic hepatitis C: prevalence of NS3 and NS5A resistance data in the state of New South Wales. <i>Antiviral Therapy</i> , 2019 , 24, 281-290	1.6	3
56	In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 991-1001	3.4	10
55	Optimizing the treatment strategy to achieve hepatitis C virus elimination in Mexico. <i>Revista De Gastroenterología De México</i> , 2019 , 84, 267-268	0.7	1
54	Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. <i>Journal of Hepatology</i> , 2019 , 70, 1019-1023	13.4	36
53	Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. <i>Future Microbiology</i> , 2019 , 14, 89-110	2.9	8
52	Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020 , 30, 126932	2.9	1
51	Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 548-551	3.4	3
50	Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. <i>Hepatology</i> , 2020 , 71, 686-721	11.2	236
49	Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology Research</i> , 2020 , 50, 1234-1243	5.1	6
48	Elimination of Hepatitis C in Portugal: An Urban Legend?. <i>GE Portuguese Journal of Gastroenterology</i> , 2020 , 27, 166-171	1.1	2
47	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020 , 73, 1170-1218	13.4	237
46	DJivu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures-Same Satisfactory Results, Same Unanswered Questions. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3296-e3299	11.6	
45	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020 , 119, 1871-1875	3.2	2
44	Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. <i>Hepatology Communications</i> , 2020 , 4, 904-915	6	2
43	Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report. <i>Zeitschrift Fur Gastroenterologie</i> , 2020 , 58, 451-455	1.6	1
42	Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020 , 30, 127361	2.9	0
41	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. <i>Liver International</i> , 2020 , 40, 2660	7.9	2
40	Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 585-592	3.4	5

39	Exosomal glypican-1 for risk stratification of pancreatic cystic lesions: A case of pathological progression in the absence of any suspicious imaging finding. <i>Pancreatology</i> , 2020 , 20, 571-575	3.8	3
38	NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. <i>International Journal of Infectious Diseases</i> , 2020 , 95, 84-89	10.5	4
37	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021 , 74, 801-810	13.4	12
36	Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection. <i>Journal of Clinical and Translational Hepatology</i> , 2021 , 9, 125-132	5.2	1
35	Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. <i>Frontiers in Microbiology</i> , 2020 , 11, 617375	5.7	1
34	Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil. <i>Infection and Drug Resistance</i> , 2021 , 14, 723-730	4.2	1
33	Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours. <i>Journal of Global Antimicrobial Resistance</i> , 2021 , 24, 311-315	3.4	
32	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. <i>Hepatology International</i> , 2021 , 15, 338-349	8.8	7
31	Clinical Experience of Patients With Hepatitis C Treated With Direct-Acting Antivirals After Heart Transplantation. <i>Transplantation Proceedings</i> , 2021 , 53, 665-672	1.1	0
30	Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors. <i>Journal of Medical Virology</i> , 2021 , 93, 1075-1081	19.7	
29	Naturally Occurring Resistance Associated Substitutions in Non-Cirrhotic, Treatment Naive HCV-HIV Co-Infected Patients Does Not Affect the Treatment Response for Anti-HCV Antiviral Therapy. <i>Infection and Drug Resistance</i> , 2021 , 14, 1381-1387	4.2	1
28	Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China. <i>Journal of Clinical and Translational Hepatology</i> , 2021 , 9, 419-427	5.2	1
27	Treatment failure with DAA therapy: Importance of resistance. <i>Journal of Hepatology</i> , 2021 , 74, 1472-1482	3.4	18
26	Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1256-1264	3.4	5
25	Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. <i>World Journal of Gastroenterology</i> , 2021 , 27, 4004-4017	5.6	1
24	Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. <i>Journal of Hepatology</i> , 2021 , 75, 462-473	13.4	8
23	Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. <i>World Journal of Hepatology</i> , 2021 , 13, 1069-1078	3.4	0
22	Strategies for hepatitis C virus treatment failure. <i>Journal of the Formosan Medical Association</i> , 2021 ,	3.2	

21	Linkage of resistance-associated substitutions in GT1 sofosbuvir+ NS5A inhibitor failures treated with glecaprevir/pibrentasvir. <i>Journal of Hepatology</i> , 2021 , 75, 820-828	13.4	1
20	Sofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review. <i>Revista De Gastroenterología De México</i> , 2021 ,	0.7	
19	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020 , 40, 1841-1852	7.9	28
18	Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 251-260	6.9	25
17	Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?. <i>World Journal of Hepatology</i> , 2018 , 10, 543-548	3.4	12
16	The Role of RASs /RVs in the Current Management of HCV. <i>Viruses</i> , 2021 , 13,	6.2	2
15	Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C. <i>Future Virology</i> , 2019 , 14, 715-727	2.4	
14	Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAAs.		
13	Sofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review. <i>Revista De Gastroenterología De México (English Edition)</i> , 2021 ,	0.2	
12	Oral antivirals in treatment naïve chronic hepatitis C infection.. <i>Hepatology</i> , 2022 ,	11.2	
11	Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,	4.6	
10	Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil. <i>Access Microbiology</i> , 2022 , 4,	1	1
9	Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 33,	2.2	0
8	Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt.. <i>Microorganisms</i> , 2022 , 10,	4.9	0
7	Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 894460	5.6	
6	Efficacy and safety of direct-acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: a multi-center, real-world study in Guangdong, China.. <i>Journal of Medical Virology</i> , 2022 ,	19.7	
5	Sofosbuvir/Velpatasvir in Adults With Hepatitis C Virus Infection and Compensated Cirrhosis in Japan. <i>Hepatology Research</i> ,	5.1	
4	Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China. 2022 , 2022, 1-8		

- 3 Management of hepatitis C virus (HCV) infection: an update. **2022**, 125, 401-405
- 2 Wushu Sports Target Tracking Algorithm Based on BP Neural Network. **2022**,
- 1 Hepatitis C: treatment. **2023**, 251-279